|
|
Article: OGS Separating Business Into Three Units To Aid Transparency.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Washington Editor
Under the direction of a new CEO, Oxford GlycoSciences plc released a plan Thursday to reduce its burn rate and improve performance by dividing its business into three separate units.
Located in Oxford, UK, OGS intends to become a research and development-based company with a focus on products for oncology and inherited storage disorders, supported by a proteomics division, David Ebsworth, OGS's CEO, told BioWorld Today.
Formerly the global head of pharmaceuticals at Bayer AG, of Leverkusen, Germany, Ebsworth came on board as OGS CEO July 1, replacing Michael Kranda, who resigned for personal reasons. In announcing the ...